The stock of Soleno Therapeutics Inc (SLNO) has seen a 1.65% increase in the past week, with a 29.17% gain in the past month, and a 49.59% flourish in the past quarter. The volatility ratio for the week is 4.53%, and the volatility levels for the past 30 days are at 5.11% for SLNO. The simple moving average for the past 20 days is 5.51% for SLNO’s stock, with a 44.63% simple moving average for the past 200 days.
Is It Worth Investing in Soleno Therapeutics Inc (NASDAQ: SLNO) Right Now?
The 36-month beta value for SLNO is also noteworthy at -2.70. There are mixed opinions on the stock, with 5 analysts rating it as a “buy,” 3 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for SLNO is 39.61M, and at present, short sellers hold a 12.65% of that float. The average trading volume of SLNO on May 09, 2025 was 1.28M shares.
SLNO) stock’s latest price update
Soleno Therapeutics Inc (NASDAQ: SLNO)’s stock price has plunge by 2.14relation to previous closing price of 74.66. Nevertheless, the company has seen a 1.65% surge in its stock price over the last five trading sessions. seekingalpha.com reported 2025-05-07 that Soleno Therapeutics, Inc. (NASDAQ:SLNO ) Q1 2025 Earnings Conference Call May 7, 2025 4:30 PM ET Company Participants Brian Ritchie – LifeSci Advisors Anish Bhatnagar – Chief Executive Officer Meredith Manning – Chief Commercial Officer Jim Mackaness – Chief Financial Officer Conference Call Participants Yasmeen Rahimi – Piper Sandler Debjit Chattopadhyay – Guggenheim Securities Kristen Kluska – Cantor Leland Gershell – Oppenheimer Brian Skorney – Baird James Condulis – Stifel Myriam Belghiti – LifeSci Capital Yale Jen – Laidlaw Operator Greetings, and welcome to the Soleno Therapeutics First Quarter 2025 Earnings Conference Call. At this time, note that all participants are in a listen-only mode.
Analysts’ Opinion of SLNO
Many brokerage firms have already submitted their reports for SLNO stocks, with Stifel repeating the rating for SLNO by listing it as a “Buy.” The predicted price for SLNO in the upcoming period, according to Stifel is $74 based on the research report published on March 05, 2025 of the current year 2025.
Stifel, on the other hand, stated in their research note that they expect to see SLNO reach a price target of $74. The rating they have provided for SLNO stocks is “Buy” according to the report published on December 02nd, 2024.
Robert W. Baird gave a rating of “Outperform” to SLNO, setting the target price at $72 in the report published on December 02nd of the previous year.
SLNO Trading at 23.91% from the 50-Day Moving Average
After a stumble in the market that brought SLNO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -0.44% of loss for the given period.
Volatility was left at 5.11%, however, over the last 30 days, the volatility rate increased by 4.53%, as shares surge +20.53% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +69.09% upper at present.
During the last 5 trading sessions, SLNO rose by +1.65%, which changed the moving average for the period of 200-days by +66.32% in comparison to the 20-day moving average, which settled at $72.27. In addition, Soleno Therapeutics Inc saw 69.66% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at SLNO starting from Hirano Patricia C, who sale 3,782 shares at the price of $70.11 back on Apr 01 ’25. After this action, Hirano Patricia C now owns 27,036 shares of Soleno Therapeutics Inc, valued at $265,156 using the latest closing price.
PATRICIA HIRANO, the Officer of Soleno Therapeutics Inc, proposed sale 3,782 shares at $70.11 during a trade that took place back on Apr 01 ’25, which means that PATRICIA HIRANO is holding shares at $265,156 based on the most recent closing price.
Stock Fundamentals for SLNO
The total capital return value is set at -0.59. Equity return is now at value -105.54, with -81.42 for asset returns.
Based on Soleno Therapeutics Inc (SLNO), the company’s capital structure generated 0.18 points at debt to capital in total, while cash flow to debt ratio is standing at -1.31. The debt to equity ratio resting at 0.22. The interest coverage ratio of the stock is -796.35.
Currently, EBITDA for the company is -173.63 million with net debt to EBITDA at 0.2. The liquidity ratio also appears to be rather interesting for investors as it stands at 19.64.
Conclusion
In summary, Soleno Therapeutics Inc (SLNO) has had a better performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
